Protein subunit vaccines: Promising frontiers against COVID-19

Chavda, Vivek P.; Ghali, Eswara Naga Hanuma Kumar; Balar, Pankti C.; Chauhan, Subhash C.; Tiwari, Nikita; Shukla, Somanshi; Athalye, Mansi; Patravale, Vandana; Apostolopoulos, Vasso; Yallapu, Murali M.

doi:10.1016/j.jconrel.2024.01.017

Cited by 9 publications

(3 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy and adaptability of subunit vaccines are underscored by their successful application in diverse pathogens, including influenza (Vogel and Manicassamy, 2020), SARS-CoV-2 Heidary et al, 2022), and RSV (Papi et al, 2023). Utilizing various platforms, such as recombinant protein vaccines (Liu et al, 2021;Chavda et al, 2024), virus-like particles (VLPs) (Sun et al, 2022), and nanoparticles (Pilkington et al, 2021), these vaccines have demonstrated considerable promise, with (Cao et al, 2022) M2e: The Matrix 2 ectodomain of influenza virus; NTD: The N-Terminal domain of the SARS-CoV-2 spike protein; HA1 trimer: trimerized hemagglutinin 1 of influenza virus; RBD trimer: trimerized receptor binding site of SARS-CoV-2 spike protein; IAV: influenza A virus.…”

Section: Combined Subunit Vaccinesmentioning

confidence: 99%

“…The efficacy and adaptability of subunit vaccines are underscored by their successful application in diverse pathogens, including influenza ( Vogel and Manicassamy, 2020 ), SARS-CoV-2 ( Dong Y. et al., 2020 ; Heidary et al., 2022 ), and RSV ( Papi et al., 2023 ). Utilizing various platforms, such as recombinant protein vaccines ( Liu et al., 2021 ; Chavda et al., 2024 ), virus-like particles (VLPs) ( Sun et al., 2022 ), and nanoparticles ( Pilkington et al., 2021 ), these vaccines have demonstrated considerable promise, with several vaccines receiving approval for human use or currently undergoing clinical trials. Moreover, subunit vaccines serve as a highly adaptable platform for the development of combined vaccines, capable of targeting multiple strains of viruses like human papillomavirus (HPV) and influenza ( Liu et al., 2021 ; Williamson, 2023 ).…”

Section: Combined Subunit Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines

Wang,

Wei,

Liu

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

In the post-COVID-19 era, the co-circulation of respiratory viruses, including influenza, SARS-CoV-2, and respiratory syncytial virus (RSV), continues to have significant health impacts and presents ongoing public health challenges. Vaccination remains the most effective measure for preventing viral infections. To address the concurrent circulation of these respiratory viruses, extensive efforts have been dedicated to the development of combined vaccines. These vaccines utilize a range of platforms, including mRNA-based vaccines, viral vector vaccines, and subunit vaccines, providing opportunities in addressing multiple pathogens at once. This review delves into the major advancements in the field of combined vaccine research, underscoring the strategic use of various platforms to tackle the simultaneous circulation of respiratory viruses effectively.

show abstract

Section: Combined Subunit Vaccinesmentioning

confidence: 99%

“…The efficacy and adaptability of subunit vaccines are underscored by their successful application in diverse pathogens, including influenza ( Vogel and Manicassamy, 2020 ), SARS-CoV-2 ( Dong Y. et al., 2020 ; Heidary et al., 2022 ), and RSV ( Papi et al., 2023 ). Utilizing various platforms, such as recombinant protein vaccines ( Liu et al., 2021 ; Chavda et al., 2024 ), virus-like particles (VLPs) ( Sun et al., 2022 ), and nanoparticles ( Pilkington et al., 2021 ), these vaccines have demonstrated considerable promise, with several vaccines receiving approval for human use or currently undergoing clinical trials. Moreover, subunit vaccines serve as a highly adaptable platform for the development of combined vaccines, capable of targeting multiple strains of viruses like human papillomavirus (HPV) and influenza ( Liu et al., 2021 ; Williamson, 2023 ).…”

Section: Combined Subunit Vaccinesmentioning

confidence: 99%

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines

Wang,

Wei,

Liu

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…This targeted approach allows for selecting immunogenic components to induce a robust immune response while minimizing the risk of adverse reactions associated with whole pathogen vaccines [ 13 ]. Moreover, compared to other modalities such as mRNA vaccines, subunit vaccines are made of protein, which is generally stored at refrigeration temperatures and does not need ultra-cold storage, simplifying storage and transportation logistics [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model

Wongnak,

Brindha,

Oba

et al. 2024

Molecules

View full text Add to dashboard Cite

The Omicron BA.5 variant of SARS-CoV-2 is known for its high transmissibility and its capacity to evade immunity provided by vaccine protection against the (original) Wuhan strain. In our prior research, we successfully produced the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein in an E. coli expression system. Extensive biophysical characterization indicated that, even without glycosylation, the RBD maintained native-like conformational and biophysical properties. The current study explores the immunogenicity and neutralization capacity of the E. coli-expressed Omicron BA.5 RBD using a mouse model. Administration of three doses of the RBD without any adjuvant elicited high titer antisera of up to 7.3 × 105 and up to 1.6 × 106 after a booster shot. Immunization with RBD notably enhanced the population of CD44+CD62L+ T cells, indicating the generation of T cell memory. The in vitro assays demonstrated the antisera’s protective efficacy through significant inhibition of the interaction between SARS-CoV-2 and its human receptor, ACE2, and through potent neutralization of a pseudovirus. These findings underscore the potential of our E. coli-expressed RBD as a viable vaccine candidate against the Omicron variant of SARS-CoV-2.

show abstract

Coronavirus spike protein-based vaccines. Vaccine delivery systems

Asrorov,

Ayubov,

et al. 2024

Medicine in Drug Discovery

View full text Add to dashboard Cite

Protein subunit vaccines: Promising frontiers against COVID-19

Cited by 9 publications

References 140 publications

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines

Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model

Coronavirus spike protein-based vaccines. Vaccine delivery systems

Contact Info

Product

Resources

About